Abbott: ABT-089 data for adult ADHD look promising

In two posters presented at the American Psychiatric Association annual meeting in Washington DC, Phase II data has demonstrated that once and twice-daily dosing of Abbott's ABT-089 is efficacious and safe in adults with ADHD. Furthermore, if it reaches the market, the drug's potential to decrease smoking behavior in adult patients is expected to give it a competitive edge over established brands.

Published By Datamonitor

ADHD children not coming to attention of doctors

School can be a difficult place at the best of times, however for the 20 million plus children in the seven major pharmaceutical markets that suffer from attention deficit and hyperactivity disorder (ADHD), it can be especially troubling. This exacerbated by the fact that many patients aren't receiving the best available treatment, according to new research from Datamonitor.

Published By Datamonitor

ADHD: 7,000 fewer UK diagnoses by 2010

Published By Datamonitor

ADHD: attending to safety deficits

An FDA safety committee is to meet in February to discuss how ADHD drug safety risks can be better assessed. The meeting will give further insight into how the FDA plans to deal with the problem, and the regulator's proposals may include recommending drug makers conduct extra long-term treatment trials. This would be a wise move in the interests of drug companies, patients and physicians alike.

Published By Datamonitor

ADHD: Eli Lilly's Strattera set to drive global market

Published By Datamonitor

ADHD: FDA debates black box warnings

In a controversial move, an FDA panel has recommended against ADHD drugs bearing "black box" warnings about psychiatric and cardiovascular risks in children. While the regulator's final decision will be eagerly awaited by both patients and drug makers alike it looks like Eli Lilly's Strattera will remain standing strong whatever the ruling.

Published By Datamonitor

ADHD: immature adult market continues to offer greatest commercial potential

Published By Datamonitor

ADHD: stimulants set for a depression in sales

Published By Datamonitor

Alcoholism drug market: shift in disease perception required for long-term growth

Estimated to be worth just $86 million in 2006, the alcohol dependence pharmaceutical market is set to grow to $304 million by 2016, driven by the launch of two pipeline opioid antagonists and the continued uptake of Alkermes and Cephalon's opioid antagonist Vivitrol. However, for substantial long-term success in drug treatment for alcohol dependence, a shift in disease perception is required.

Published By Datamonitor

Alkermes and Cephalon: Vivitrol's sales likely to be unaffected by FDA's warning

The FDA has warned of the risk of injection site reactions to Vivitrol, a once-monthly injection drug for the treatment of alcohol dependence. However, due to the considerable adverse health consequences related to alcohol dependence, along with the limited number of prescription drugs available, Datamonitor does not expect Vivitrol to experience a substantial downturn in sales.

Published By Datamonitor